Polyphor announces listing of new shares related to the convertible loan facility agreement with the Wellcome Trust Dienstag, 17. Juli 2018 - 07:00

Polyphor AG / Key word(s): Miscellaneous
Polyphor announces listing of new shares related to the convertible loan
facility agreement with the Wellcome Trust

17-Jul-2018 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Polyphor announces listing of new shares related to the convertible loan
facility agreement with the Wellcome Trust

Polyphor today announced that 15'758 new registered shares issued from the
authorized capital have been listed today on SIX Swiss Exchange. In April
2018 Polyphor and the Wellcome Trust entered into an amendment agreement to
the convertible loan facility agreement made available to Polyphor by the
Wellcome Trust. In this amendment agreement the Wellcome Trust exercised its
right to convert the outstanding loan amount in full immediately prior to
the completion of the listing of Polyphor's shares. These shares have a
lock-up period ending one year after the first day of trading.


For further information please contact:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company which has
discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead product, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical
priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology
candidate, balixafortide (POL6326), which has achieved clinical proof of
concept in a Phase Ib/proof of concept study in combination with eribulin in
patients with advanced breast cancer, and a pipeline of further preclinical
antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near
Basel and is listed on the Swiss Stock Exchange (SIX: POLN). For more
information, please visit www.polyphor.com.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------